Compare Alcon AG (ALC) vs Invesco Ltd. (IVZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Invesco Ltd. — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Invesco Ltd. trades at $27.06 (market cap $12.15B). The key difference: Alcon AG is far larger — about 2.7× Invesco Ltd.'s market cap, and Invesco Ltd. pays the higher dividend (3.14%). Which is the better fit depends on your goals.
| ALC | IVZ | |
|---|---|---|
Market Cap | $32.69B | $12.15B |
Sector | Health | Financials |
52-Week High | $92.22 | $29.44 |
52-Week Low | $62.02 | $16.69 |
Enterprise Value | $36.28B | $22.39B |
Dividend Yield | 0.54% | 3.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Invesco (IVZ) trades at $27.40, up 1.44% today, with a bullish technical signal from moving averages and support at $27. The company reported mixed Q1 2026 earnings, missing estimates, but has beaten expectations in two prior quarters. Revenue grew to $6.38B in 2025, though net income was negative at -$281.70M. Operating cash flow remains strong at $1.53B, and a dividend of $0.22 is scheduled for June 2026.
Outlook: Analyst consensus is mixed with 43% buy ratings and a $29.44 price target, suggesting modest upside. Risks include persistent negative profitability and competitive pressures in asset management. The stock offers value with a P/E of 19.48 but requires monitoring of earnings turnaround and expense management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
